Full FDA approval of Pfizer’s Covid-19 vaccine may ease the path to booster shots in the U.S., a plan that’s received mixed reactions amid spiking infections from the delta variant and global inequity in immunization access.
Sept. 20 is the day the Biden administration plans to open the doors for most Americans to begin getting third doses of Covid-19 vaccines, pending sign-off from the Food and Drug Administration and recommendations from the Centers for Disease Control and Prevention. The plan has been on a bumpy road as policy experts debate the need for a booster—the CDC has already pushed back ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.